313 related articles for article (PubMed ID: 12881518)
21. The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and Genistein is effective in inhibiting pancreatic cancer growth.
Nozawa F; Itami A; Saruc M; Kim M; Standop J; Picha KS; Cowan KH; Pour PM
Pancreas; 2004 Jul; 29(1):45-52. PubMed ID: 15211111
[TBL] [Abstract][Full Text] [Related]
22. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A
Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602
[TBL] [Abstract][Full Text] [Related]
23. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
Kelley SK; Harris LA; Xie D; Deforge L; Totpal K; Bussiere J; Fox JA
J Pharmacol Exp Ther; 2001 Oct; 299(1):31-8. PubMed ID: 11561060
[TBL] [Abstract][Full Text] [Related]
24. Safety and antitumor activity of recombinant soluble Apo2 ligand.
Ashkenazi A; Pai RC; Fong S; Leung S; Lawrence DA; Marsters SA; Blackie C; Chang L; McMurtrey AE; Hebert A; DeForge L; Koumenis IL; Lewis D; Harris L; Bussiere J; Koeppen H; Shahrokh Z; Schwall RH
J Clin Invest; 1999 Jul; 104(2):155-62. PubMed ID: 10411544
[TBL] [Abstract][Full Text] [Related]
25. Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin.
Bauer JA; Morrison BH; Grane RW; Jacobs BS; Dabney S; Gamero AM; Carnevale KA; Smith DJ; Drazba J; Seetharam B; Lindner DJ
J Natl Cancer Inst; 2002 Jul; 94(13):1010-9. PubMed ID: 12096086
[TBL] [Abstract][Full Text] [Related]
26. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
Poulaki V; Mitsiades CS; Kotoula V; Tseleni-Balafouta S; Ashkenazi A; Koutras DA; Mitsiades N
Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389
[TBL] [Abstract][Full Text] [Related]
27. The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis.
Mace TA; Yamane N; Cheng J; Hylander BL; Repasky EA
Immunol Invest; 2006; 35(3-4):279-96. PubMed ID: 16916755
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling.
Harper N; Hughes MA; Farrow SN; Cohen GM; MacFarlane M
J Biol Chem; 2003 Nov; 278(45):44338-47. PubMed ID: 12920112
[TBL] [Abstract][Full Text] [Related]
29. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression.
Huerta-Yepez S; Vega M; Jazirehi A; Garban H; Hongo F; Cheng G; Bonavida B
Oncogene; 2004 Jun; 23(29):4993-5003. PubMed ID: 15048072
[TBL] [Abstract][Full Text] [Related]
30. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
31. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
[TBL] [Abstract][Full Text] [Related]
32. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
33. TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines.
Yoshida S; Narita T; Koshida S; Ohta S; Takeuchi Y
Pediatr Res; 2003 Nov; 54(5):709-17. PubMed ID: 12904602
[TBL] [Abstract][Full Text] [Related]
34. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells.
Kim YS; Schwabe RF; Qian T; Lemasters JJ; Brenner DA
Hepatology; 2002 Dec; 36(6):1498-508. PubMed ID: 12447876
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.
Wu XX; Kakehi Y; Mizutani Y; Nishiyama H; Kamoto T; Megumi Y; Ito N; Ogawa O
Int J Cancer; 2003 Apr; 104(4):409-17. PubMed ID: 12584736
[TBL] [Abstract][Full Text] [Related]
36. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.
Ehrhardt H; Fulda S; Schmid I; Hiscott J; Debatin KM; Jeremias I
Oncogene; 2003 Jun; 22(25):3842-52. PubMed ID: 12813457
[TBL] [Abstract][Full Text] [Related]
37. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death.
Thomas RP; Farrow BJ; Kim S; May MJ; Hellmich MR; Evers BM
Surgery; 2002 Aug; 132(2):127-34. PubMed ID: 12219002
[TBL] [Abstract][Full Text] [Related]
38. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells.
Milani D; Zauli G; Rimondi E; Celeghini C; Marmiroli S; Narducci P; Capitani S; Secchiero P
J Neurochem; 2003 Jul; 86(1):126-35. PubMed ID: 12807432
[TBL] [Abstract][Full Text] [Related]
39. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase.
Lin Y; Devin A; Cook A; Keane MM; Kelliher M; Lipkowitz S; Liu ZG
Mol Cell Biol; 2000 Sep; 20(18):6638-45. PubMed ID: 10958661
[TBL] [Abstract][Full Text] [Related]
40. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
